Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Jazz Pharmaceuticals's total debt was $5.57B at Sep 30, 2026. For fiscal 2025 it was $5.36B, down 12.3% from the year before. Over ten years it grew 16.3% a year on average. The highest annual figure on record is $6.11B in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.36B | -12.3% |
| FY2024 | Dec 31, 2024 | $6.11B | +6.9% |
| FY2023 | Dec 31, 2023 | $5.71B | -0.2% |
| FY2022 | Dec 31, 2022 | $5.72B | -5.4% |
| FY2021 | Dec 31, 2021 | $6.05B | +188.8% |
| FY2020 | Dec 31, 2020 | $2.09B | +30.3% |
| FY2019 | Dec 31, 2019 | $1.61B | +0.7% |
| FY2018 | Dec 31, 2018 | $1.60B | +1.0% |
| FY2017 | Dec 31, 2017 | $1.58B | -22.1% |
| FY2016 | Dec 31, 2016 | $2.03B | +70.8% |
| FY2015 | Dec 31, 2015 | $1.19B | -11.5% |
| FY2014 | Dec 31, 2014 | $1.34B | +144.1% |
| FY2013 | Dec 31, 2013 | $549.98M | +20.4% |
| FY2012 | Dec 31, 2012 | $456.76M | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.57B | +3.9% |
| Q2 FY2026 | Jun 30, 2026 | $4.35B | -18.9% |
| Q1 FY2026 | Mar 31, 2026 | $5.35B | -0.2% |
| Q4 FY2025 | Dec 31, 2025 | $5.36B | -12.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.36B | -12.3% |
| Q2 FY2025 | Jun 30, 2025 | $5.36B | -6.0% |
| Q1 FY2025 | Mar 31, 2025 | $5.37B | -6.0% |
| Q4 FY2024 | Dec 31, 2024 | $6.11B | +6.9% |
| Q3 FY2024 | Sep 30, 2024 | $6.11B | +6.9% |
| Q2 FY2024 | Jun 30, 2024 | $5.71B | -0.2% |
| Q1 FY2024 | Mar 31, 2024 | $5.71B | -0.2% |
| Q4 FY2023 | Dec 31, 2023 | $5.71B | -0.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.72B | -0.2% |
| Q2 FY2023 | Jun 30, 2023 | $5.72B | -5.0% |
| Q1 FY2023 | Mar 31, 2023 | $5.72B | -5.0% |
| Q4 FY2022 | Dec 31, 2022 | $5.72B | -5.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.73B | -8.8% |
| Q2 FY2022 | Jun 30, 2022 | $6.02B | -10.6% |
| Q1 FY2022 | Mar 31, 2022 | $6.02B | +186.6% |
| Q4 FY2021 | Dec 31, 2021 | $6.05B | +188.8% |
| Q3 FY2021 | Sep 30, 2021 | $6.28B | +200.7% |
| Q2 FY2021 | Jun 30, 2021 | $6.74B | +220.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.10B | +30.5% |
| Q4 FY2020 | Dec 31, 2020 | $2.09B | +30.3% |
| Q3 FY2020 | Sep 30, 2020 | $2.09B | +30.1% |
| Q2 FY2020 | Jun 30, 2020 | $2.10B | +31.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.61B | +0.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.61B | +0.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.60B | +0.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.60B | +0.6% |
| Q1 FY2019 | Mar 31, 2019 | $1.60B | +1.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.60B | +1.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.59B | +0.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.59B | -4.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.58B | -15.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.58B | -22.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.58B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.67B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.88B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.03B | – |
See a number that looks wrong?